| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.057 | 0.2 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.036 | 0.5 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.014 | 0.8 |